Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS)

What is the purpose of this trial?

This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS. Ocrelizumab will be administered as two intravenous (IV) infusions of 300 milligrams (mg) on Days 1 and 15. Subsequent doses will be given as single 600-mg infusions. Participants will be randomized to receive lumbar puncture (LP) post-treatment at Week 12, 24, or 52.


Participation Guidelines

Ages: 18 - 55 years

Gender: Both


Genentech Foundation for Biomedical Sciences

Start Date: 06/29/2016

End Date: 09/30/2018

Last Updated: 02/22/2018

Study HIC#: 1602017292

Get Involved

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

David A. Hafler

Principal Investigator

Sub-Investigators